| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bd7a45a343acd10e3f5d8775dda2157 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2017-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0be4bca47981ff34028b0af49f2734ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f8debc27af0c4c0d1beb974909b9e34 |
| publicationDate |
2021-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-I731157-B |
| titleOfInvention |
ErbB2 REGULATES AUTOPHAGIC FLUX TO MODULATE THE PROTEOSTASIS OF APP-CTFs IN ALZHEIMER'S DISEASE |
| abstract |
Use of an ErbB2 inhibitor for promoting ErbB2- regulated autophagic ndegradation or clearance of APP-C99 and APP intracellular domain (AICD) and/or alleviating production of Aβ40 and Aβ42 in a subject in need thereof is disclosed. Use of an ErbB2 inhibitor for rescuing ErbB2-mediated inhibition of autophagic flux in a subject in need thereof is also disclosed. Use of an ErbB2 inhibitor for enhancing spatial learning and memory, and/or for cognitive improvement, in a subject with ErbB2-associated Alzheimer's disease is further disclosed. Also disclosed is use of an nErbB2 inhibitor for reducing intracellular levels of C99 and AICD without affecting extracellular domain-truncated Notch and Notch intracellular domain in a subject in need thereof. |
| priorityDate |
2016-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |